Talazoparib in patients with advanced breast cancer and a germline BRCA mutation

New England Journal of Medicine

Volumn 379, Issue 8, 2018, Pages 753-763

  Litton, Jennifer K ^a,k   Rugo, Hope S ^c   Ettl, Johannes ^g   Hurvitz, Sara A ^e   Gonçalves, Anthony ⁱ   Lee, Kyung Hun ^k   Fehrenbacher, Louis ^f   Yerushalmi, Rinat ^m   Mina, Lida A ⁿ   Martin, Miguel ^o   Roché, Henri ^j   Im, Young Hyuck ^l   Quek, Ruben G W ^d   Markova, Denka ^d   Tudor, Iulia C ^d   Hannah, Alison L ^d   Eiermann, Wolfgang ^h   Blum, Joanne L ^b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b Developmental Therapeutics Committee and Co Chair of the Genitourinary Committee   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d PFIZER INC   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f KAISER PERMANENTE   (United States)

^g TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^h Interdisciplinary Oncology Center   (Germany)

ⁱ INSTITUT PAOLI CALMETTES   (France)

^j INSTITUT CLAUDIUS REGAUD   (France)

^k Seoul National University Hospital   (South Korea)

^l Samsung Medical Center   (South Korea)

^m RABIN MEDICAL CENTER   (Israel)

ⁿ Banner MD Anderson Cancer Center   (United States)

^o UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE; ERIBULIN; GEMCITABINE; TALAZOPARIB; VINORELBINE TARTRATE; ANTINEOPLASTIC AGENT; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; PHTHALAZINE DERIVATIVE;

ACUTE MYELOID LEUKEMIA; ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; BREAST CANCER; CANCER GROWTH; CONFIDENCE INTERVAL; CONTROLLED STUDY; DEATH; DIARRHEA; DRUG CHOICE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEMALE; GENE MUTATION; GERMLINE MUTATION; GLOBAL HEALTH; HAZARD RATIO; HEMATOLOGIC DISEASE; HUMAN; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; ODDS RATIO; OPEN STUDY; PATIENT-REPORTED OUTCOME; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PHYSICIAN; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROMYELOCYTIC LEUKEMIA; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SEPSIS; SIDE EFFECT; THERAPY DELAY; THROMBOCYTOPENIA; TIME TO TREATMENT; TUMOR SUPPRESSOR GENE; VERY ELDERLY; BREAST TUMOR; CLINICAL TRIAL; DISEASE FREE SURVIVAL; GENETICS; MIDDLE AGED; MULTICENTER STUDY; SURVIVAL ANALYSIS;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; GENES, BRCA1; GENES, BRCA2; GERM-LINE MUTATION; HUMANS; MIDDLE AGED; PATIENT REPORTED OUTCOME MEASURES; PHTHALAZINES; POLY(ADP-RIBOSE) POLYMERASE INHIBITORS; QUALITY OF LIFE; SURVIVAL ANALYSIS;

EID: 85052504313     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1802905     Document Type: Article

References (15)

1. Helleday T. The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings. Mol Oncol 2011; 5: 387-93.
2. Javle M, Curtin NJ. The potential for poly (ADP-ribose) polymerase inhibitors in cancer therapy. Ther Adv Med Oncol 2011; 3: 257-67.
3. Lord CJ, Ashworth A. PARP inhibitors synthetic lethality in the clinic. Science 2017; 355: 1152-8.
4. Murai J, Huang SY, Das BB, et al. Trapping of PARP1 and PARP2 by clinical PARP inhibitors. Cancer Res 2012; 72 5588-99.
5. Murai J, Huang SY, Renaud A, et al. Stereospecific PARP trapping by BMN 673 and comparison with olaparib and rucaparib. Mol Cancer Ther 2014; 13: 433-43.
6. Rouleau M, Patel A, Hendzel MJ Kaufmann SH, Poirier GG. PARP inhibition PARP1 and beyond. Nat Rev Cancer 2010; 10: 293-301.
7. Shen Y, Rehman FL, Feng Y, et al. BMN 673, a novel and highly potent PARP1/2 inhibitor for the treatment of human cancers with DNA repair deficiency. Clin Cancer Res 2013; 19: 5003-15.
8. de Bono J, Ramanathan RK, Mina L et al. Phase I, dose-escalation, two-part trial of the PARP inhibitor talazoparib in patients with advanced germline BRCA1/2 mutations and selected sporadic cancers. Cancer Discov 2017; 7: 620-9.
9. Turner NC, Telli ML, Rugo HS, et al. Final results of a phase 2 study of talazoparib (TALA) following platinum or multiple cytotoxic regimens in advanced breast cancer patients (pts) with germline BRCA1/2 mutations (ABRAZO). Presented at the American Society of Clinical Oncology 2017 Annual Meeting, Chicago, June 2-6, 2017. abstract.
10. Haybittle JL. Repeated assessment of results in clinical trials of cancer treatment. Br J Radiol 1971; 44: 793-7.
11. Peto R, Pike MC, Armitage P, et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. I. Introduction and design. Br J Cancer 1976; 34: 585-612.
12. Osoba D, Rodrigues G, Myles J, Zee B Pater J. Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol 1998; 16: 139-44.
13. Robson M, Im S-A, Senkus E, et al. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N Engl J Med 2017; 377: 523-33.
14. Byrski T, Dent R, Blecharz P, et al. Results of a phase II open-label, non-randomized trial of cisplatin chemotherapy in patients with BRCA1-positive metastatic breast cancer. Breast Cancer Res 2012; 14: R110.
15. Tutt A, Tovey H, Cheang MCU, et al. Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups the TNT Trial. Nat Med 2018; 24 628-37.